179 related articles for article (PubMed ID: 38409164)
1. Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice.
Ranjbarvaziri S; Zeng A; Wu I; Greer-Short A; Farshidfar F; Budan A; Xu E; Shenwai R; Kozubov M; Li C; Van Pell M; Grafton F; MacKay CE; Song X; Priest JR; Argast G; Mandegar MA; Hoey T; Yang J
Nat Commun; 2024 Feb; 15(1):1352. PubMed ID: 38409164
[TBL] [Abstract][Full Text] [Related]
2. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.
Li Y; Kubo H; Yu D; Yang Y; Johnson JP; Eaton DM; Berretta RM; Foster M; McKinsey TA; Yu J; Elrod JW; Chen X; Houser SR
Am J Physiol Heart Circ Physiol; 2023 Apr; 324(4):H443-H460. PubMed ID: 36763506
[TBL] [Abstract][Full Text] [Related]
3. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
Dulce RA; Kanashiro-Takeuchi RM; Takeuchi LM; Salerno AG; Wanschel ACBA; Kulandavelu S; Balkan W; Zuttion MSSR; Cai R; Schally AV; Hare JM
Cardiovasc Res; 2023 Feb; 118(18):3586-3601. PubMed ID: 35704032
[TBL] [Abstract][Full Text] [Related]
4. Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Wu H; Tang LX; Wang XM; Li LP; Chen XK; He YJ; Yang DZ; Shi Y; Shou JL; Zhang ZS; Wang L; Lu BJ; An SM; Zeng CY; Wang WE
Acta Pharmacol Sin; 2023 Jun; 44(6):1149-1160. PubMed ID: 36473990
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy.
Yang J; Grafton F; Ranjbarvaziri S; Budan A; Farshidfar F; Cho M; Xu E; Ho J; Maddah M; Loewke KE; Medina J; Sperandio D; Patel S; Hoey T; Mandegar MA
Sci Transl Med; 2022 Jul; 14(652):eabl5654. PubMed ID: 35857625
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate-activated Citrate Synthase.
Zhang X; Wang N; Fu P; An Y; Sun F; Wang C; Han X; Zhang Y; Yu X; Liu Y
J Cardiovasc Pharmacol; 2023 Nov; 82(5):375-388. PubMed ID: 37643027
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction.
Zhang N; Ma Q; You Y; Xia X; Xie C; Huang Y; Wang Z; Ye F; Yu Z; Xie X
Int J Biol Sci; 2022; 18(3):1271-1287. PubMed ID: 35173552
[No Abstract] [Full Text] [Related]
10. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
Alex L; Russo I; Holoborodko V; Frangogiannis NG
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
[TBL] [Abstract][Full Text] [Related]
11. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction.
Zuo GF; Wang LG; Huang L; Ren YF; Ge Z; Hu ZY; Zhang JJ; Chen SL
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166979. PubMed ID: 38065272
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation.
Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y
J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806
[TBL] [Abstract][Full Text] [Related]
13. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF.
Deng Y; Xie M; Li Q; Xu X; Ou W; Zhang Y; Xiao H; Yu H; Zheng Y; Liang Y; Jiang C; Chen G; Du D; Zheng W; Wang S; Gong M; Chen Y; Tian R; Li T
Circ Res; 2021 Jan; 128(2):232-245. PubMed ID: 33176578
[TBL] [Abstract][Full Text] [Related]
14. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2.
Dong S; Ma W; Hao B; Hu F; Yan L; Yan X; Wang Y; Chen Z; Wang Z
Int J Clin Exp Pathol; 2014; 7(2):565-74. PubMed ID: 24551276
[TBL] [Abstract][Full Text] [Related]
15. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction.
Cheng X; Zhao H; Wen X; Li G; Guo S; Zhang D
Life Sci; 2023 Nov; 333():122185. PubMed ID: 37858713
[TBL] [Abstract][Full Text] [Related]
16. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
Packer M
J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
[TBL] [Abstract][Full Text] [Related]
17. Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice.
Roh JD; Houstis N; Yu A; Chang B; Yeri A; Li H; Hobson R; Lerchenmüller C; Vujic A; Chaudhari V; Damilano F; Platt C; Zlotoff D; Lee RT; Shah R; Jerosch-Herold M; Rosenzweig A
Aging Cell; 2020 Jun; 19(6):e13159. PubMed ID: 32441410
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
